Gibson Dunn has advised Avere Therapeutics. Sidley Austin has advised NextCure. Avere Therapeutics, Inc., a privately-held biotechnology company, and NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company,...
Avere Therapeutics and NextCure Announce Merger with $320 Million Private Placement
HealthCare Royalty Monetizes Royalties on Modeyso Sales
Sidley has advised HealthCare Royalty on the transaction. HealthCare Royalty has entered into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics, Inc....
Obsidian Therapeutics and Galera Therapeutics Announce $350 Million Merger and Private Placement
Goodwin Procter LLP has advised Obsidian Therapeutics. Sidley Austin LLP has advised Galera Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the placement...
Sensei Biotherapeutics Acquires Faeth Therapeutics and Raises US$200 Million in Private Placement
Sidley has advised Sensei Biotherapeutics on the deal. Sensei Biotherapeutics, Inc. has completed the acquisition of Faeth Therapeutics and undertaken a private placement expected to generate...
Immunovant Raises $550 Million in Common Stock Offering
Sidley Austin LLP has advised Immunovant, Inc. Latham & Watkins LLP has advised the underwriter. Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company focused on developing...
Pharvaris Announces US$201.2 Million Public Offering of Shares and Pre-Funded Warrants
NautaDutilh N.V. and Kirkland & Ellis LLP have advised Pharvaris N.V. on the offering, and Sidley Austin LLP and Loyens & Loeff N.V. have advised underwriters....
Marvel Fusion’s Series B Funding Round
Sidley Austin represented Siemens Energy in the transaction. Marvel Fusion GmbH, a German company at the forefront of developing technology aimed at harnessing fusion energy, has...
Accelerate Diagnostics’ Successful Restructuring
Sidley advised Accelerate Diagnostics on the operation. Accelerate Diagnostics, Inc. completed the out of court restructuring of its $92 million in funded debt. The company closed...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...